Highlights

  • Healius (ASX:HLS) reported a 76.6% increase in underlying EBIT during FY26, supported by improved pathology margins and cost initiatives.
  • Pathology EBITDA Margin improved to 18.6% for FY26, with second-half margins showing further improvement.
  • The company reported a statutory net loss of $415.6 million, impacted by Impairment charges and discontinued operations.
  • FY27 performance will depend on margin sustainability, cost control measures and portfolio optimisation initiatives.

Healius Limited (ASX:HLS) delivered a mixed FY26 result, highlighting meaningful progress in its underlying operational recovery while also reflecting the financial challenges associated with its broader Business reset. The company reported a significant improvement in underlying profitability, supported by stronger pathology margins, cost reduction initiatives and a simplified portfolio following the Lumus Imaging divestment. However, the statutory result remained under pressure, with a sizeable net loss and no Dividend declared for FY26.

Latest Development

The company’s FY26 performance showed improvement in underlying Earnings rather than significant Revenue expansion. Group underlying revenue from continuing operations increased 2.1% to $1,373.2 million, while underlying EBIT rose to $30.2 million from $17.1 million in the previous year, representing a 76.6% increase. Underlying EBITDA also increased 8.1% to $258.6 million.

The statutory result reflected a different picture, with Healius reporting a statutory EBIT loss of $328.9 million. This included a $332.0 million pre-tax Goodwill impairment charge, while the company recorded a statutory net loss of $415.6 million including discontinued operations. On an underlying basis, the group recorded a loss of $13.2 million, improving from the $24.8 million shortfall reported previously.

The board did not declare an interim, final or Special Dividend for FY26, reflecting the company’s current focus on Balance Sheet management and operational recovery.

Financial Performance

Pathology remained the key contributor to the recovery. Divisional revenue increased 1.8% to $1,329.6 million, while pathology EBITDA grew 6.4% to $247.9 million. The segment’s EBITDA margin improved by 80 basis points to 18.6%.

The second-half performance provided an important indicator of operational progress, with pathology EBITDA margin reaching 19.7% compared with 17.6% in the first half. This improvement reflected the impact of cost discipline, productivity initiatives and improvements in revenue mix.

Cost management remained a major focus during the year. Annualised support-cost savings reached $24.4 million, exceeding the company’s targeted range. Full-time headcount declined by around 5%, while consumables spending reduced to 15.3% of revenue.

Despite the operational improvement, the balance sheet experienced a shift during FY26. Healius ended the year with net Debt of $32.8 million compared with a net cash position of $57.2 million at the beginning of the period, reflecting capital expenditure, Lease payments and ongoing business restructuring activities.

Business Drivers

Healius’ strategy continues to centre around portfolio simplification and improving the quality of earnings. The sale of Lumus Imaging allowed the company to reposition itself as a more focused pathology operator while strengthening its capital position.

Growth areas include higher-value services such as Genomic Diagnostics, business-to-business Clinical Trials and veterinary pathology. Average fees per episode increased 4.0%, supported by changes in service mix and operational improvements.

Technology initiatives have also become an important part of the company’s transformation strategy. Digital upgrades, including improvements to collections processes and workforce planning systems, are aimed at improving efficiency and supporting longer-term margin recovery.

Healius is also assessing strategic Options for Agilex Biolabs, its clinical-trials laboratory business. Agilex delivered revenue growth of 14.1% to $43.6 million in FY26, while EBITDA increased to $10.7 million.

Investor Focus

Several factors will remain important for Healius investors as the company moves into FY27.

  • The outcome of the Agilex Biolabs strategic review could influence capital allocation and balance sheet flexibility.
  • Maintaining second-half pathology EBITDA margins will be important in determining whether recent improvements can continue.
  • FY27 earnings delivery will remain a key focus, with management expecting EBIT broadly aligned with market expectations of around $39.7 million.
  • Rising labour costs, including wage increases and additional employment-related expenses, could continue to affect margins.
  • Progress on the T27 transformation program will be monitored, with completion timing extended towards December 2028.

Risks

Healius continues to operate in a labour-intensive healthcare environment where cost pressures remain a key challenge. Pathology volumes remain relatively stable, while reimbursement settings and regulatory factors continue to influence industry conditions.

The company also faces execution risks as it works through its transformation program. Previous goodwill impairments and the latest statutory loss highlight the challenges involved in restoring sustainable profitability.

With no dividend declared for FY26 and debt returning to the balance sheet, investors will likely continue focusing on earnings improvement, cash generation and the durability of margin recovery.

Outlook

FY26 represented progress for Healius’ underlying operations, with improved margins, lower costs and a more focused business structure supporting the recovery effort. However, the statutory loss, dividend suspension and ongoing cost pressures demonstrate that the turnaround remains incomplete.

The company’s future performance will depend on whether recent pathology margin improvements can be sustained, whether transformation initiatives deliver further efficiencies and how effectively management balances Investment with financial discipline.